SCHEMBL7095446

SCHEMBL7095446

COc1ccc(Oc2c(I)cc([N+](=O)[O-])cc2I)cc1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
THRB P10828 8/20 0.47
RORC P51449 4/20 0.47
THRA P10827 4/20 0.42
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965062 0.86 THRB (0.48) THRBRORCTHRALMNASMN1; SMN2
SCHEMBL2047460 0.85 THRB (0.51) THRBRORCTHRALMNASMN1; SMN2
SCHEMBL5327698 0.85 RORC (0.62) THRBRORCTHRALMNASMN1; SMN2
SCHEMBL7256878 0.82 KIF11 (0.45) THRBRORCTHRALMNASMN1; SMN2
SCHEMBL282551 0.80 THRB (0.55) THRBRORCTHRAMEN1KMT2A
SCHEMBL6435329 0.78 THRB (0.44) THRBRORCTHRALMNASMN1; SMN2
SCHEMBL11039034 0.78 RORC (0.47) THRBRORCTHRATDP1MEN1
SCHEMBL14264309 0.78 RORC (0.53) THRBRORCTHRAMAPT
SCHEMBL2962266 0.76 SMN1; SMN2 (0.60) LMNASMN1; SMN2TDP1MEN1KMT2A
SCHEMBL14264313 0.75 RORC (0.56) THRBRORCTHRATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030166731-A1 Method of treating hair loss using diphenylether derivatives THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 2003-09-04 US disclosed
US-6525094-B1 Topical application of compound that interacts strongly with thyroid hormone receptors but sparingly with heart selective hormone receptors THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 2003-02-25 US disclosed
EP-1185230-A1 METHOD OF TREATING HAIR LOSS USING DIPHENYLETHER DERIVATIVES UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2002-03-13 EP disclosed
WO-2000072812-A1 METHOD OF TREATING HAIR LOSS USING DIPHENYLETHER DERIVATIVES THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166731-A1 Method of treating hair loss using diphenylether derivatives CYP27A1, DHCR7, CYP11A1 THRB 716/4885RORC 1125/4885THRA 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.